Acadia Pharmaceuticals annual operating margin
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Acadia Pharmaceuticals's operating margin was 9.78% for fiscal 2025.
View full Acadia Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 9.78% | −14.31 pp |
| 2024 | 2024-12-31 | 24.10% | +34.20 pp |
| 2023 | 2023-12-31 | −10.10% | +33.13 pp |
| 2022 | 2022-12-31 | −43.23% | −8.02 pp |
| 2021 | 2021-12-31 | −35.20% | +29.67 pp |
| 2020 | 2020-12-31 | −64.87% | +7.84 pp |
| 2019 | 2019-12-31 | −72.71% | +37.85 pp |
| 2018 | 2018-12-31 | −110.56% | +123.55 pp |
| 2017 | 2017-12-31 | −234.11% | +1340.03 pp |
| 2016 | 2016-12-31 | −1,574.14% | +268281.59 pp |
| 2015 | 2015-12-31 | −269,855.74% | −192164.07 pp |
| 2014 | 2014-12-31 | −77,691.67% | −74346.95 pp |
| 2013 | 2013-12-31 | −3,344.72% | −2919.08 pp |
| 2012 | 2012-12-31 | −425.64% | +679.93 pp |
| 2011 | 2011-12-31 | −1,105.56% | −1141.39 pp |
| 2010 | 2010-12-31 | 35.82% | +746.37 pp |
| 2009 | 2009-12-31 | −710.55% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 12.29% | +0.05 pp |
| Q1 2026 | 2026-03-31 | −1.72% | −9.62 pp |
| Q4 2025 | 2025-12-31 | 6.12% | −53.01 pp |
| Q3 2025 | 2025-09-30 | 12.83% | +0.20 pp |
| Q2 2025 | 2025-06-30 | 12.24% | −0.34 pp |
| Q1 2025 | 2025-03-31 | 7.90% | +0.51 pp |
| Q4 2024 | 2024-12-31 | 59.13% | +44.01 pp |
| Q3 2024 | 2024-09-30 | 12.64% | +39.93 pp |
| Q2 2024 | 2024-06-30 | 12.58% | +10.74 pp |
| Q1 2024 | 2024-03-31 | 7.39% | +52.62 pp |
| Q4 2023 | 2023-12-31 | 15.12% | +48.87 pp |
| Q3 2023 | 2023-09-30 | −27.29% | −3.68 pp |
| Q2 2023 | 2023-06-30 | 1.84% | +26.85 pp |
| Q1 2023 | 2023-03-31 | −45.23% | +52.64 pp |
| Q4 2022 | 2022-12-31 | −33.75% | +0.40 pp |
| Q3 2022 | 2022-09-30 | −23.61% | −11.99 pp |
| Q2 2022 | 2022-06-30 | −25.01% | +12.93 pp |
| Q1 2022 | 2022-03-31 | −97.88% | −35.21 pp |
| Q4 2021 | 2021-12-31 | −34.15% | +21.35 pp |
| Q3 2021 | 2021-09-30 | −11.63% | +59.61 pp |
| Q2 2021 | 2021-06-30 | −37.93% | +2.04 pp |
| Q1 2021 | 2021-03-31 | −62.66% | +36.72 pp |
| Q4 2020 | 2020-12-31 | −55.50% | +1.86 pp |
| Q3 2020 | 2020-09-30 | −71.24% | −23.22 pp |
| Q2 2020 | 2020-06-30 | −39.97% | +28.64 pp |
| Q1 2020 | 2020-03-31 | −99.39% | +39.81 pp |
| Q4 2019 | 2019-12-31 | −57.36% | +55.57 pp |
| Q3 2019 | 2019-09-30 | −48.02% | +57.07 pp |
| Q2 2019 | 2019-06-30 | −68.61% | +43.68 pp |
| Q1 2019 | 2019-03-31 | −139.19% | −27.01 pp |
| Q4 2018 | 2018-12-31 | −112.93% | +47.78 pp |
| Q3 2018 | 2018-09-30 | −105.09% | +79.42 pp |
| Q2 2018 | 2018-06-30 | −112.30% | +110.96 pp |
| Q1 2018 | 2018-03-31 | −112.18% | +468.23 pp |
| Q4 2017 | 2017-12-31 | −160.71% | +493.28 pp |
| Q3 2017 | 2017-09-30 | −184.51% | +1189.81 pp |
| Q2 2017 | 2017-06-30 | −223.25% | +73924.17 pp |
| Q1 2017 | 2017-03-31 | −580.41% | +1255969.59 pp |
| Q4 2016 | 2016-12-31 | −654.00% | +267375.42 pp |
| Q3 2016 | 2016-09-30 | −1,374.32% | +98620.56 pp |
| Q2 2016 | 2016-06-30 | −74,147.42% | +3875552.58 pp |
| Q1 2016 | 2016-03-31 | −1,256,550.00% | −242750.00 pp |
| Q4 2015 | 2015-12-31 | −268,029.41% | −207274.09 pp |
| Q3 2015 | 2015-09-30 | −99,994.87% | +66631.79 pp |
| Q2 2015 | 2015-06-30 | −3,949,700.00% | −3872117.86 pp |
| Q1 2015 | 2015-03-31 | −1,013,800.00% | −953940.00 pp |
| Q4 2014 | 2014-12-31 | −60,755.32% | −27876.94 pp |
| Q3 2014 | 2014-09-30 | −166,626.67% | −162122.08 pp |
| Q2 2014 | 2014-06-30 | −77,582.14% | −75551.77 pp |
| Q1 2014 | 2014-03-31 | −59,860.00% | −58381.82 pp |
| Q4 2013 | 2013-12-31 | −32,878.38% | −31083.90 pp |
| Q3 2013 | 2013-09-30 | −4,504.58% | −4435.38 pp |
| Q2 2013 | 2013-06-30 | −2,030.38% | −1124.03 pp |
| Q1 2013 | 2013-03-31 | −1,478.18% | −93.51 pp |
| Q4 2012 | 2012-12-31 | −1,794.47% | −890.73 pp |
| Q3 2012 | 2012-09-30 | −69.21% | +802.88 pp |
| Q2 2012 | 2012-06-30 | −906.34% | +524.96 pp |
| Q1 2012 | 2012-03-31 | −1,384.67% | −37.31 pp |
| Q4 2011 | 2011-12-31 | −903.74% | −719.39 pp |
| Q3 2011 | 2011-09-30 | −872.09% | −685.06 pp |
| Q2 2011 | 2011-06-30 | −1,431.30% | — |
| Q1 2011 | 2011-03-31 | −1,347.36% | — |
| Q3 2010 | 2010-09-30 | −184.35% | — |
| Q2 2010 | 2010-06-30 | −187.03% | — |
Over the last five reported fiscal years, Acadia Pharmaceuticals's operating margin increased from −64.87% to 9.78%, a change of +74.66 percentage points. The latest reported quarter, Q2 2026, shows 12.29%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acadia Pharmaceuticals filings at SEC.gov ↗